WebJun 13, 2024 · Novartis Pharmaceuticals (1) Collaborator. Intervention. dff332 (1) nir178 (1) pdr001 (1) rad001 (1) Study Documents. Intervention Type. drug (1) Funder Type. Industry … WebGlobal Tel: +41 61 324 11 11 Fax: +41 61 324 80 01 (Switzerland) Monday - Friday 8:30 a.m. - 5:00 p.m. GMT+1 United States Tel: +1 862 778 21 00 Monday - Friday 8:30 a.m. - 5:00 p.m. EST For product-related inquiries and medical information about our products, please contact the Novartis office in your country. Share
Innovative Medicines Novartis
WebFeb 3, 2024 · This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab ... WebNov 30, 2024 · DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab … building manager jobs
Contacts Novartis
WebOctober 25, 2024. DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other … WebThe purpose of this study is to find the highest and safest dose of the investigational drug DFF332 that can be given alone or in combination with other anticancer drugs in people … WebHypoxia-Inducible Factor 2 Alpha (HIF2ホア) Inhibitors: Targeting Genetically Driven Tumor Hypoxia Endocrine Reviews Oxford Academic Abstract. Tumors driven by deficiency of the VHL gene product, which is involved in degradation of the hypoxia-inducible factor subunit 2 alpha (HIF2ホア), are nat crown leafcutter bee trays